Compare SSNC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSNC | GH |
|---|---|---|
| Founded | 1986 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 17.3B |
| IPO Year | 2007 | 2018 |
| Metric | SSNC | GH |
|---|---|---|
| Price | $65.42 | $168.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 19 |
| Target Price | $96.13 | ★ $119.79 |
| AVG Volume (30 Days) | 2.0M | ★ 2.6M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | 5.00 | ★ 6.74 |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $1,675,295,000.00 | $982,021,000.00 |
| Revenue This Year | $9.20 | $33.30 |
| Revenue Next Year | $4.69 | $28.27 |
| P/E Ratio | $71.98 | ★ N/A |
| Revenue Growth | 13.09 | ★ 32.88 |
| 52 Week Low | $61.40 | $40.36 |
| 52 Week High | $91.07 | $172.61 |
| Indicator | SSNC | GH |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 78.43 |
| Support Level | $65.15 | $94.02 |
| Resistance Level | $70.24 | N/A |
| Average True Range (ATR) | 1.79 | 6.98 |
| MACD | -0.19 | 2.85 |
| Stochastic Oscillator | 55.50 | 91.92 |
SS&C Technologies provides software products and software-enabled services to a variety of customers primarily in financial services. Acquisitions are a large part of SS&C's history. SS&C GlobeOp provides fund administration services to alternative and traditional asset managers. In addition, SS&C provides portfolio accounting, portfolio management, trading, banking/lending, and other software to asset managers, banks, and financial advisors. SS&C's purchase of Intralinks makes it a leading player in virtual deal room solutions. With its 2018 purchase of DST Systems, SS&C gained a foothold in the healthcare industry with pharmacy health management solutions and medical claim administration services. In 2022, SS&C acquired robotic process automation software firm Blue Prism.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.